Commercial strategy

Valuation and licensing deal modelling

From forecast to risk-adjusted value and deal terms, so the science and the numbers stay linked.

What we do

We convert a patient-based forecast into a product-level financial view, then estimate risk-adjusted value from development costs, timelines and probability of success by phase. Value is presented as a range tied to scenarios.

For licensing discussions we model upfront payments, milestones and tiered royalties, and show how a structure splits value between the two sides. The same workbook can be reused when a counteroffer arrives.

This is analytical support for your own decision. It is not investment advice, a fairness opinion or a formal business valuation.

How it works

Four steps, nothing hidden.

  1. 1

    Link

    Connect the patient-based forecast to revenue, costs and timing.

  2. 2

    Risk-adjust

    Apply probability of success by phase and discount to today.

  3. 3

    Structure

    Model the deal terms and the value each party receives.

  4. 4

    Test

    Show what moves the value and what a counteroffer changes.

Questions teams ask

Before you start.

What is risk-adjusted net present value?

It is the value of an asset's expected future cash flows after weighting each stage by its probability of success and discounting to today.

Where do the success rates come from?

Published benchmark rates by phase and therapeutic area. Any asset-specific adjustment is marked as an assumption.

Is this a formal valuation?

No. It is analysis to support your decision, not investment advice or a formal business valuation.